Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
3 papers in the library · 19 citations · publishing 2023-2026
European Neuropsychopharmacology February 15, 2023 Santiago Madero, O. D. Alvarez 12 citations
The COVID-19 pandemic has had widespread effects on health, society, and the economy. The text does not provide specific findings, arguments, or data beyond referencing the pandemic itself.
Dialogues in clinical neuroscience December 1, 2025 Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al. 4 citations
As the global population ages, depression in older adults is increasingly common, yet conventional antidepressants often have limited effectiveness and problematic side effects. Psychedelic compounds are emerging as a potential alternative. This review examines preclinical and clinical evidence suggesting psychedelics could treat major depressive disorder in the elderly. It discusses the neurobiological mechanisms behind these effects, highlights relevant animal models, and addresses safety concerns. The authors propose strategies to improve the efficacy and safety of psychedelic therapy in future clinical trials, offering a new avenue for treating late-life depression.
JAMA Psychiatry March 25, 2026 Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al. 3 citations
A single day of treatment with an inhaled synthetic formulation of mebufotenin (GH001) significantly reduced depression symptoms in adults with treatment-resistant depression compared to placebo. In a randomized, double-blind trial of 81 patients, those receiving up to three escalating doses of GH001 showed an average 15.5-point greater improvement on the Montgomery-Åsberg Depression Rating Scale by day 8 than those on placebo. Remission rates were 57.5% for GH001 and 0% for placebo. No severe or serious adverse events occurred. The findings suggest GH001 may be a rapid-acting, well-tolerated treatment option for treatment-resistant depression.